AU2020243514A1 - Use of vibegron to treat overactive bladder - Google Patents
Use of vibegron to treat overactive bladder Download PDFInfo
- Publication number
- AU2020243514A1 AU2020243514A1 AU2020243514A AU2020243514A AU2020243514A1 AU 2020243514 A1 AU2020243514 A1 AU 2020243514A1 AU 2020243514 A AU2020243514 A AU 2020243514A AU 2020243514 A AU2020243514 A AU 2020243514A AU 2020243514 A1 AU2020243514 A1 AU 2020243514A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- vibegron
- placebo
- treatment
- treatment period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025256180A AU2025256180A1 (en) | 2019-03-18 | 2025-10-23 | Use Of Vibegron To Treat Overactive Bladder |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820230P | 2019-03-18 | 2019-03-18 | |
| US62/820,230 | 2019-03-18 | ||
| US201962830302P | 2019-04-05 | 2019-04-05 | |
| US62/830,302 | 2019-04-05 | ||
| US201962842435P | 2019-05-02 | 2019-05-02 | |
| US62/842,435 | 2019-05-02 | ||
| US201962885767P | 2019-08-12 | 2019-08-12 | |
| US62/885,767 | 2019-08-12 | ||
| US201962897019P | 2019-09-06 | 2019-09-06 | |
| US62/897,019 | 2019-09-06 | ||
| US201962904429P | 2019-09-23 | 2019-09-23 | |
| US62/904,429 | 2019-09-23 | ||
| PCT/IB2020/052484 WO2020188505A1 (en) | 2019-03-18 | 2020-03-18 | Use of vibegron to treat overactive bladder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025256180A Division AU2025256180A1 (en) | 2019-03-18 | 2025-10-23 | Use Of Vibegron To Treat Overactive Bladder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020243514A1 true AU2020243514A1 (en) | 2021-08-26 |
Family
ID=70166082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020243514A Abandoned AU2020243514A1 (en) | 2019-03-18 | 2020-03-18 | Use of vibegron to treat overactive bladder |
| AU2025256180A Pending AU2025256180A1 (en) | 2019-03-18 | 2025-10-23 | Use Of Vibegron To Treat Overactive Bladder |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025256180A Pending AU2025256180A1 (en) | 2019-03-18 | 2025-10-23 | Use Of Vibegron To Treat Overactive Bladder |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230027066A1 (https=) |
| EP (1) | EP3941473A1 (https=) |
| JP (2) | JP2022524576A (https=) |
| KR (2) | KR20210142004A (https=) |
| CN (2) | CN121489955A (https=) |
| AU (2) | AU2020243514A1 (https=) |
| BR (1) | BR112021017198A2 (https=) |
| CA (1) | CA3129024A1 (https=) |
| IL (1) | IL285910A (https=) |
| MX (1) | MX2021009488A (https=) |
| PH (1) | PH12021551975A1 (https=) |
| SG (1) | SG11202108810YA (https=) |
| TW (2) | TW202102221A (https=) |
| WO (1) | WO2020188505A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634420A1 (en) | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| SG11202103662VA (en) | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| TW202245781A (zh) * | 2021-02-16 | 2022-12-01 | 瑞士商優洛凡特科學公司 | 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| WO2013062881A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| RS59402B1 (sr) | 2013-03-15 | 2019-11-29 | Merck Sharp & Dohme | Postupak za pripremu beta 3 agonista i međuproizvoda |
| JP6197971B1 (ja) * | 2016-04-22 | 2017-09-20 | 小野薬品工業株式会社 | Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤 |
| US20170348288A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| US10057209B2 (en) * | 2016-07-28 | 2018-08-21 | Qualcomm Incorporated | Time-sequenced multi-device address assignment |
| JP7670461B2 (ja) * | 2017-06-06 | 2025-04-30 | ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング | 過活動膀胱の治療のためのビベグロンの投薬 |
| EP3634420A1 (en) * | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| EP3583905A1 (en) * | 2018-06-20 | 2019-12-25 | Arthrex Inc | Percutaneous targeting device |
-
2020
- 2020-03-18 JP JP2021545837A patent/JP2022524576A/ja active Pending
- 2020-03-18 US US17/440,612 patent/US20230027066A1/en active Pending
- 2020-03-18 SG SG11202108810Y patent/SG11202108810YA/en unknown
- 2020-03-18 MX MX2021009488A patent/MX2021009488A/es unknown
- 2020-03-18 BR BR112021017198A patent/BR112021017198A2/pt unknown
- 2020-03-18 EP EP20716934.3A patent/EP3941473A1/en active Pending
- 2020-03-18 TW TW109109041A patent/TW202102221A/zh unknown
- 2020-03-18 KR KR1020217033037A patent/KR20210142004A/ko not_active Ceased
- 2020-03-18 AU AU2020243514A patent/AU2020243514A1/en not_active Abandoned
- 2020-03-18 CN CN202511459167.9A patent/CN121489955A/zh active Pending
- 2020-03-18 PH PH1/2021/551975A patent/PH12021551975A1/en unknown
- 2020-03-18 WO PCT/IB2020/052484 patent/WO2020188505A1/en not_active Ceased
- 2020-03-18 TW TW113116798A patent/TW202506129A/zh unknown
- 2020-03-18 KR KR1020267009764A patent/KR20260049872A/ko active Pending
- 2020-03-18 CA CA3129024A patent/CA3129024A1/en active Pending
- 2020-03-18 CN CN202080036713.7A patent/CN113840607A/zh active Pending
-
2021
- 2021-08-26 IL IL285910A patent/IL285910A/en unknown
-
2025
- 2025-02-07 JP JP2025018962A patent/JP2025084777A/ja active Pending
- 2025-10-23 AU AU2025256180A patent/AU2025256180A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113840607A (zh) | 2021-12-24 |
| SG11202108810YA (en) | 2021-10-28 |
| AU2025256180A1 (en) | 2025-11-13 |
| MX2021009488A (es) | 2021-09-21 |
| TW202506129A (zh) | 2025-02-16 |
| WO2020188505A1 (en) | 2020-09-24 |
| CN121489955A (zh) | 2026-02-10 |
| JP2022524576A (ja) | 2022-05-09 |
| EP3941473A1 (en) | 2022-01-26 |
| JP2025084777A (ja) | 2025-06-03 |
| BR112021017198A2 (pt) | 2021-11-16 |
| CA3129024A1 (en) | 2020-09-24 |
| TW202102221A (zh) | 2021-01-16 |
| PH12021551975A1 (en) | 2022-07-04 |
| IL285910A (en) | 2021-10-31 |
| KR20210142004A (ko) | 2021-11-23 |
| KR20260049872A (ko) | 2026-04-14 |
| US20230027066A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deeks | Mirabegron: A Review in Overactive Bladder Syndrome: ED Deeks | |
| AU2025256180A1 (en) | Use Of Vibegron To Treat Overactive Bladder | |
| McKeage | Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms | |
| US20110319384A1 (en) | Pharmaceutical Compositions | |
| CA2657043A1 (en) | Use of flibanserin for the treatment of sexual disorders in females | |
| JP2025032143A (ja) | 良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用 | |
| US20230270738A1 (en) | Methods of treating agitation associated with alzheimer's disease | |
| US20250387382A1 (en) | Methods of treating essential tremor | |
| US20210196720A1 (en) | Use of vibegron to treat pain associated with irritable bowel syndrome | |
| EP1622450A2 (en) | Method for promoting uninterrupted sleep by administration of trospium chloride | |
| EP4422628A1 (en) | Methods of treating agitation associated with alzheimer's disease | |
| HK40126413A (en) | Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia | |
| EA052961B1 (ru) | Вибегрон для лечения симптомов гиперактивного мочевого пузыря | |
| WO2026085384A1 (en) | Methods of treating essential tremor | |
| JP4372723B2 (ja) | 慢性疼痛の治療のための医薬の製造に有用な組成物 | |
| BR122024021845A2 (pt) | Usos de vibegron para tratar sintomas de bexiga hiperativa e reduzir ou diminuir as micções |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted | ||
| PC1 | Assignment before grant (sect. 113) |
Owner name: SUMITOMO PHARMA CO., LTD Free format text: FORMER APPLICANT(S): UROVANT SCIENCES GMBH |